ARESTYR ONCOLOGIC
Arestyr OncoLogic is a biotechnology company that develops both diagnostics and therapies for cancer. Its proprietary technology is based on its unique understanding of a specific molecular structure found in late-stage cancer cells. Arestyr’s technology targets these cells by generating an immune response in the form of antibodies. The antibodies then serve as a biomarker to show where the cancer cells are located.
Similar Organizations
AlphaSense
AlphaSense is a neurotechnology company, headquartered in Boston starting from 2013.
Anteros Pharmaceuticals
Anteros Pharmaceuticals is a biotechnology company that develops drugs for fibrotic and other inflammatory diseases.
Athna Biotech
Athna Biotech specializes in developing novel nanotherapeutics for cancer.
Biotrics Bioimplants
Biotrics Bioimplants is a biotechnology company that develops biomaterials for oral tissue regeneration.
Fustibal
Fustibal is a biotechnology startup that develops antibody-based nanomedicines for multi-targeted cancer therapy.
Gearbox Biosciences
Gearbox Biosciences is a biotechnology company that provides new technology for the decoupling of protein production from cell growth.
Optherion
Optherion, Inc., a biotechnology company, develops diagnostic and disease-modifying therapeutics for the management and treatment of
OPTOLANE Technologies
OPTOLANE Technologies is a biotechnology company that develops a diagnosis platform.
PlusVitech
PlusVitech develops effective and safe therapeutic treatments and complementary diagnostic tests for cancer patients.
More informations about "Arestyr OncoLogic"
Arestyr OncoLogic - PitchBook
Arestyr OncoLogic General Information Description. Operator of a biotech company based in Thousand Oaks, California. The company specializes in both diagnostics and therapies for …See details»
Arestyr OncoLogic, Inc. Company Profile | Thousand Oaks, CA ...
Find company research, competitor information, contact details & financial data for Arestyr OncoLogic, Inc. of Thousand Oaks, CA. Get the latest business insights from Dun & Bradstreet.See details»
Arestyr OncoLogic
Arestyr OncoLogic is a biotech company developing both diagnostics and therapies for cancer. The company’s proprietary technology is based on its unique understanding of a specific …See details»
Arestyr Oncologic, Inc. in Thousand Oaks CA - Company Profile
Arestyr Oncologic, Inc. Overview. Arestyr Oncologic, Inc. filed as a Statement & Designation By Foreign Corporation in the State of California on Monday, April 23, 2018 and is approximately …See details»
ARESTYR ONCOLOGIC, INC. :: California (US) - OpenCorporates
Apr 23, 2018 Free and open company data on California (US) company ARESTYR ONCOLOGIC, INC. (company number 4144883), 22 W AVENIDA DE LAS FLORES …See details»
Arestyr Oncologic, Inc. Thousand Oaks, CA - filing information
Arestyr Oncologic, Inc., a Stock Corporation, is a business entity located in Thousand Oaks, CA. Officially filed on April 23, 2018, this corporation is recognized under the document number …See details»
Arestyr OncoLogic - Drug pipelines, Patents, Clinical trials - Synapse
Last update 11 Jul 2024. Arestyr OncoLogic. Private CompanySee details»
ARESTYR ONCOLOGIC, INC. :: Delaware (US) - OpenCorporates
Free and open company data on Delaware (US) company ARESTYR ONCOLOGIC, INC. (company number 6151752)See details»
Arestyr OncoLogic - Crunchbase
Arestyr OncoLogic is a biotechnology company that develops both diagnostics and therapies for cancer.See details»
Arestyr Oncologic, Inc. in Thousand Oaks, CA - (805) 279-2337
Arestyr Oncologic, Inc. is in the Biotechnical Research, Commercial business. View competitors, revenue, employees, website and phone number.See details»
Optherion - Crunchbase
Optherion, Inc., a biotechnology company, develops diagnostic and disease-modifying therapeutics for the management and treatment ofSee details»
OICR funds world-first clinical trial using cancer-fighting viruses
Jan 5, 2016 Drs. John Bell, David Stojdl and Brian Lichty have together been investigating viral therapies for over 15 years. On July 10 in Ottawa they announced that this work has now …See details»
Serum TK1 is a more reliable marker than CEA and AFP for cancer ...
Nov 1, 2016 The World Health Organization (WHO) has estimated that the number of cancer patients will increase by about 70% during the next 25 years world-wide. To deal with this …See details»
Histology-specific long-term oncologic outcomes in patients with ...
4 days ago Objective Assessing the histology-specific prognosis of epithelial ovarian cancer (OvCa) is clinically challenging, especially in a patient population with a favorable prognosis. …See details»
Elacestrant (Orserdu) for Metastatic Breast Cancer Treatment
Aug 9, 2024 Research table: Elacestrant (Orserdu) for metastatic breast cancer treatment This summary table contains detailed information about research studies. Summary tables are a …See details»
Comparative analysis of treatment modalities for solitary, small …
2 days ago This study compares oncologic outcomes after ablation, liver resection, and liver transplantation for solitary, small hepatocellular carcinoma. Methods We systematically …See details»
Bastyr Leads Innovation in Cancer Treatment and Prevention
Oct 9, 2015 “These are not theoretical findings,” stresses Leanna Standish, PhD, ND, LAc, FABNO, professor at the Bastyr University Research Institute. “This is not wishful thinking. I’m …See details»
A Systematic Review and Meta‐Analysis of Oncologic Liver …
This study aimed to review the current status of research in LMICs regarding outcomes after oncologic hepatectomy and synthesize the data reported in the literature. Methods. The …See details»
Organization of Cancer Specialists in US Physician Practices and …
Jun 28, 2023 The organization of cancer care differs within versus outside of health systems, and proximity to a large NCI Cancer Center does not necessarily imply a high cancer specialist …See details»